Trial Profile
A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 11 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.